Compare MUX & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MUX | DMRA |
|---|---|---|
| Founded | 1979 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 1994 | 2020 |
| Metric | MUX | DMRA |
|---|---|---|
| Price | $20.42 | $29.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $26.63 | ★ $43.00 |
| AVG Volume (30 Days) | ★ 1.1M | 306.7K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 168.60 | 121.48 |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $197,553,000.00 | N/A |
| Revenue This Year | $37.86 | N/A |
| Revenue Next Year | $31.10 | N/A |
| P/E Ratio | $35.51 | ★ N/A |
| Revenue Growth | ★ 13.23 | N/A |
| 52 Week Low | $12.38 | $16.50 |
| 52 Week High | $29.70 | $34.89 |
| Indicator | MUX | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 57.07 | 46.05 |
| Support Level | $20.44 | $28.16 |
| Resistance Level | $20.62 | $34.23 |
| Average True Range (ATR) | 0.83 | 1.50 |
| MACD | 0.19 | -0.25 |
| Stochastic Oscillator | 61.92 | 4.72 |
McEwen Inc, formerly McEwen Mining Inc is a mining and minerals production and exploration company that focuses on precious and base minerals in Argentina, Mexico, and the United States. The company generates its revenue from gold and silver production. It owns and operates the wholly-owned El Gallo 1 mine in Mexico and holds a minority stake in the company that manages the San Jose mine in Argentina. More than half of the company's gold output comes from the El Gallo 1 mine, while the remaining gold production and the majority of silver production are sourced from the San Jose mine. Geographically, majority of production occurs in the United States.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.